Table 1 Characteristics of include studies
Author/year | Region | Size | Age (years) | Male (%) | Follow-up | Study type | Intervention | Outcome | Adjustment |
|---|---|---|---|---|---|---|---|---|---|
Eiji Ichimoto/2009 [28] | Japan | 71 | 64 | 62 (87.3) | 5.6 months | Retrospective | PCI | Cardiovascular events | Age; Killip class; Time from hospital presentation to angioplasty; Prior myocardial infarction; Creatinine; |
Doroteia Silva/2012 [7] | Japan | 151 | 61 | 115 (76.2) | 19.2 months | Prospective | PCI | Death/reinfarction | Ejection fraction ≤ 40%; |
Tong-Wen Sun/2012 [8] | China | 605 | 60.4 | 404 (66.8%) | 14.3 months | Prospective | PCI | Major adverse cardiac events | NA; |
Ozgur Akgul/2013 [9] | Turkey | 475 | 55.8 | 380 (80%) | 1 month | Prospective | PCI | Major adverse cardiac events | Age; gender; diabetes; hypertension; Killip class; anemia; renal failure; No-reflow; Three-vessel disease; unsuccessful procedure; LVEF < 40%; |
Fabio Angeli/2015 [29] | Italy | 2757 | 63 | 2123 (77%) | 2 years | Prospective | PCI | All-cause mortality | Age; gender; diabetes; unsuccessful PCI; LVEF; Multivessel disease; Statin prescription at discharge; eGFR; |
Seung Hyun Lee/2015 [18] | Korea | 1033 | 65.2 | 806 (78%) | 2.9 years | Prospective | CABG | Mortality and major adverse cerebrovascular and cardiovascular events | NA; |
Alain Dardashti/2016 [30] | Sweden | 1638 | 67.4 | 1295 (79.1%) | 3.5 years | Prospective | CABG | All-cause mortality | Age; LVEF < 30%; logarithm of time in ICU; hemoglobin; plasma transfused; creatinine; |
Guidong Shen/2018 [31] | China | 664 | 57.6 | 565 (85.1%) | 3.2 years | Retrospective | PCI | Major adverse cardiac events | Age; SBP ≥ 140 (mmHg); NT-proBNP; eGFR; LVEF < 40%; |